Neurogene (NASDAQ:NGNE) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Posted by Doug Wharley on Mar 26th, 2025

Neurogene (NASDAQ:NGNE – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.99) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.04) by $0.05, Zacks reports. The business had revenue of $0.93 million for the quarter.

Neurogene Trading Up 1.7 %

Shares of NASDAQ NGNE opened at $14.20 on Wednesday. Neurogene has a 12-month low of $13.47 and a 12-month high of $74.49. The stock has a 50 day simple moving average of $17.01 and a 200-day simple moving average of $29.15.

Insider Activity at Neurogene

In related news, CFO Christine Mikail Cvijic sold 4,501 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $16.94, for a total value of $76,246.94. Following the completion of the transaction, the chief financial officer now owns 72,343 shares in the company, valued at $1,225,490.42. This represents a 5.86 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 9.92% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. William Blair reissued an “outperform” rating on shares of Neurogene in a report on Tuesday. HC Wainwright cut their price target on Neurogene from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $59.80.

View Our Latest Stock Analysis on NGNE

Neurogene Company Profile

(Get Free Report)

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.